Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 2:11 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 577–600 of 7,024 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Healthy Volunteers. Clear all

Conditions: Cognitive Decline, Alzheimer Disease
Interventions: [18F]AV-1451; Drug
Lead sponsor: University of Pennsylvania; Other
Eligibility: 65 Years and older
Enrollment: 111 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2027
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Healthy
Interventions: Olanzapine; Drug
Lead sponsor: Dost Ongur; Other
Eligibility: 21 Years to 50 Years
Enrollment: 35 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Belmont, Massachusetts

Conditions: Oxygen Saturation
Interventions: Clarifi Modulum, Perimed PeriFlux 5000, Apple Watch Oxygen Sensor, Innovo iP 900AP; Device
Lead sponsor: Indiana University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022
U.S. locations: 2
States / cities: Indianapolis, Indiana • Pittsburgh, Pennsylvania

Conditions: Healthy Volunteers
Interventions: AZD4831; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022
U.S. locations: 1
States / cities: Brooklyn, Maryland

Conditions: Dyslipidemia
Interventions: AZD0780, Rosuvastatin; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 16 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023
U.S. locations: 1
States / cities: Brooklyn, Maryland

Conditions: Healthy
Interventions: CD388 Injection, Saline placebo; Combination Product · Drug
Lead sponsor: Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA); Industry
Eligibility: 18 Years to 65 Years
Enrollment: 77 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: HIV-1-infection
Interventions: ibalizumab-uiyk; Drug
Lead sponsor: TaiMed Biologics Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 43 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2022
U.S. locations: 4
States / cities: Los Angeles, California • Fort Lauderdale, Florida • Orlando, Florida + 1 more

Conditions: Healthy Volunteer
Interventions: celecoxib; Drug
Lead sponsor: POZEN; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 80 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008
U.S. locations: 1
States / cities: Springfield, Missouri

Conditions: COVID-19, SARS-COV-2 Infection
Interventions: BNT162b2 Vaccine, Placebo; Biological
Lead sponsor: BioNTech SE; Industry
Eligibility: 50 Years to 64 Years
Enrollment: 5,240 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 196
States / cities: Anniston, Alabama • Athens, Alabama • Birmingham, Alabama + 148 more

Conditions: Healthy Volunteers - Male and Female
Interventions: KP-001, Moxifloxacin 400 mg, Placebo; Drug
Lead sponsor: Kaken Pharmaceutical; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Glendale, California

Conditions: Hemodialysis, Healthy
Interventions: [14C] CR845; Drug
Lead sponsor: Cara Therapeutics, Inc.; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Chemotherapy-induced Nausea and Vomiting
Interventions: Rolapitant; Drug
Lead sponsor: Tesaro, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Healthy
Interventions: LY4268989; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026
U.S. locations: 1
States / cities: Daytona Beach, Florida

Conditions: Healthy
Interventions: Not listed
Lead sponsor: National Institute of Neurological Disorders and Stroke (NINDS); NIH
Eligibility: Not listed
Enrollment: 25 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2002 – 2003
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Healthy Volunteers
Interventions: A4250; Drug
Lead sponsor: Albireo; Industry
Eligibility: 19 Years to 55 Years
Enrollment: 17 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018
U.S. locations: 1
States / cities: Lincoln, Nebraska

Conditions: Healthy Volunteers
Interventions: Survey; Other
Lead sponsor: National Institutes of Health Clinical Center (CC); NIH
Eligibility: 18 Years to 120 Years
Enrollment: 75,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Healthy Participants
Interventions: DC-806, Midazolam, Repaglinide, Digoxin, Rosuvastatin; Drug
Lead sponsor: DICE Therapeutics, Inc., a wholly owned subsidiary of Eli Lilly and Company; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 28 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Traumatic Brain Injury
Interventions: Not listed
Lead sponsor: National Institute of Nursing Research (NINR); NIH
Eligibility: 18 Years to 70 Years
Enrollment: 19 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2013
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Antineutrophil Cytoplasmic Antibody Associated Vasculitis
Interventions: STSA-1002 subcutaneous injection; Drug
Lead sponsor: Staidson (Beijing) Biopharmaceuticals Co., Ltd; Industry
Eligibility: 21 Years to 57 Years
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Healthy, no Evidence of Disease
Interventions: Bowman-Birk inhibitor concentrate, placebo, pharmacological study, laboratory biomarker analysis; Drug · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years to 65 Years · Male only
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2009
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: HIV
Interventions: Atazanavir (current formulation), Atazanavir, powder for oral use 1 (POU1), Atazanavir (POU2); Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years to 49 Years
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011
U.S. locations: 1
States / cities: Lenexa, Kansas

Conditions: Healthy
Interventions: Lamotrigine; Drug
Lead sponsor: Dr. Reddy's Laboratories Limited, India; Industry
Eligibility: 18 Years to 41 Years
Enrollment: 26 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2003
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Healthy
Interventions: Selpercatinib; Drug
Lead sponsor: Loxo Oncology, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 224 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 4
States / cities: Anaheim, California • Daytona Beach, Florida • Dallas, Texas + 1 more

Conditions: Healthy
Interventions: JNJ-26366821, Placebo; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 33 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Baltimore, Maryland

Search by objective public record fields.

Tau Pet Imaging in the Aging Brain Cohort Dedicated to Diversity Study

The Effects of Antipsychotic Drugs on Brain Metabolism in Healthy Individuals

Comparison of Tissue Oxygenation Measurement Using Multimodal Devices

A Study to Assess the Relative Bioavailability and Safety of Different Formulations of AZD4831 in Fasted State in Healthy Volunteers.

A Study to Assess the Effect of AZD0780 on the Pharmacokinetics of Rosuvastatin.

Study of CD388 Intramuscular or Subcutaneous Administration in Healthy Subjects

Study of the Safety of Trogarzo™ Administered as an Undiluted "IV Push" or an Intramuscular Injection

Phase I Study to Evaluate Bioavailability of Overencapsulated Celecoxib

A Study to Learn About a COVID-19 Vaccine in Healthy Adults 50 Through 64 Years of Age

A Study to Evaluate the Effects of KP-001 on the QT/QTc Intervals in Healthy Adults

Study to Evaluate the Pharmacokinetics and Metabolism of [14C] CR845 (Difelikefalin) in Patients With End Stage Renal Disease on Hemodialysis and in Healthy Subjects

A Phase 1, 2-Part, Single Ascending Dose Assessment of the Safety, Tolerability, and Pharmacokinetics of Rolapitant Intravenous in Healthy Volunteers

A Study of LY4268989 (MORF 057) in Healthy Participants

Nerve Stimulation to Modify a Spinal Reflex

Study of A4250 in Healthy Volunteers Under Fasting, Fed and Sprinkled Conditions

Survey to Determine Incarcerated Persons' Views on Surrogate Decision Making

A Drug-Drug Interaction Study Evaluating the Perpetrator Potential of DC-806 on Cocktails of CYP450 Enzyme and Transporter Substrates in Healthy Participants

Developing Therapies for Traumatic Brain Injury

The Safety and Tolerability of STSA-1002 Following Subcutaneous Injection in Healthy Subjects

Bowman-Birk Inhibitor Concentrate in Healthy Men

Taste Assessment Study of 2 Atazanavir Powder Formulations in Healthy Subjects

Bioequivalence Study of Lamotrigine 25 mg Chewable Tablets of Dr.Reddy's Under Fed Condition

A Study Comparing Two Formulations of Selpercatinib (LY3527723) in Healthy Participants

A Study of a Single Subcutaneous Dose of JNJ-26366821 in Healthy Participants